You are here: Industry Insights > CAD

News List

US FDA approves Sanofi’s Enjaymo for cold agglutinin disease treatment pharmaceutical-business-review
February 07, 2022
The US Food and Drug Administration (FDA) has approved Sanofi’s Enjaymo (sutimlimab-jome) to treat cold agglutinin disease (CAD) in adult patients.
New Pivotal Data at EHA 2021 Reinforces Sutimlimab as a First-in-Class Investigational C1s Inhibitor with the Potential to be the First Approved Treatment for Hemolysis in People with Cold Agglutinin drugs
June 21, 2021
Results from Part A of CADENZA, a pivotal Phase 3 double-blind, placebo-controlled study evaluating the safety and efficacy of sutimlimab in people with cold agglutinin disease (CAD) without a recent history of blood transfusion.
AstraZeneca’s heart disease drug Brilinta gets FDA approval pharmaceutical-technology
June 02, 2020
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for Brilinta (ticagrelor) to decrease the risk of a first heart attack or stroke in high-risk patients suffering from coronary artery disease (CAD).
FDA grants priority review to Biologics License Application for sutimlimab europeanpharmaceuticalreview
May 21, 2020
The FDA has granted priority review of the Biologics License Application for sutimlimab to treat haemolysis in patients with cold agglutinin disease (CAD).
Low Cardiac Troponin Levels Cannot Safely Rule Out Ischemia drugs
January 16, 2020
Even very low concentrations of high-sensitivity cardiac troponin I (hs-cTnI) cannot safely rule out inducible myocardial ischemia in patients with symptomatic coronary artery disease (CAD), according to a study published online January in the Annals of I
Benefit, Harm Seen for Ticagrelor Plus Aspirin in Stable CAD With T2DM drugs
September 04, 2019
Ticagrelor plus aspirin compared with placebo plus aspirin is associated with a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding among patients with ...
Complete Revascularization Best for STEMI With Multivessel CAD drugs
September 04, 2019
For patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease, complete revascularization is superior to culprit lesion-only percutaneous coronary intervention (PCI),
Central Obesity Tied to CAD in Postmenopausal Chest Pain drugs
August 29, 2019
For postmenopausal women with stable chest pain, central obesity, but not overall obesity, is associated with obstructive coronary artery disease (CAD)...
AstraZeneca announces its Brilinta reduced MACE in CAD and type 2 diabetes patients pharmaceutical-technology
February 26, 2019
Global pharmaceutical company AstraZeneca has announced its drug Brilinta (ticagrelor) in combination with aspirin has met its primary endpoint, a statistically significant reduction in major adverse cardiovascular events, in the Phase III THEMIS trial...
Abbott initiates groundbreaking study to treat CAD biospectrumasia
April 16, 2018
Trial will assess if stent procedures guided by high-resolution imaging result in larger vessel diameters and improved patient clinical outcomes versus stent procedures that use standard-of-care imaging